Market Overview
Companion diagnostics are becoming a foundational component of modern drug development and clinical practice. These tests identify patients most likely to benefit from a specific therapy, improving treatment outcomes while reducing unnecessary exposure to ineffective medicines. The Biomarkers Market is expanding rapidly, from USD 61.00 billion in 2025 to a projected USD 181.17 billion by 2035, at an 11.5% CAGR. Companion diagnostics are particularly influential in oncology, where targeted therapies, immunotherapies, and antibody-drug conjugates require biomarker-based patient selection. Efficacy biomarkers held a 54.0% revenue share in 2025, reflecting their central role in prognostic, predictive, pharmacodynamic, and surrogate applications.

Current Market Landscape
PD-L1 testing guiding immunotherapy selection. HER2 testing supporting breast and gastric cancer treatment decisions. EGFR, ALK, and KRAS assays enabling targeted lung cancer therapy. BRCA testing identifying eligibility for PARP inhibitors. Companion diagnostic co-development agreements between pharmaceutical and diagnostics companies. Central laboratories supporting global clinical trials. Molecular tumor boards interpreting complex results. Regulatory pathways allowing broader class-level claims for oncology diagnostics. Reimbursement frameworks linking payment to therapeutic consequence. Hospitals adopting comprehensive genomic profiling. Patients receiving more individualized treatment plans. Increasing use of biomarkers beyond oncology into neurology and immunology.

Emerging Trends
Pharmaceutical and diagnostic companies are moving from simple fee-for-service partnerships toward risk-sharing agreements tied to drug uptake. This aligns incentives around commercial success and encourages diagnostics partners to support post-approval market access. Regulators are expanding companion diagnostic labeling flexibility, allowing broader claims across drug classes and reducing repeated co-development burdens. Liquid biopsy is increasingly being used alongside tissue testing to identify actionable mutations when tumor samples are limited. Artificial intelligence is improving variant classification and treatment matching. Payers are demanding stronger evidence of clinical utility, pushing laboratories to build outcomes registries and real-world evidence programs.

Future Outlook
Companion diagnostics will likely become standard across a broader range of therapeutic areas, including autoimmune disease, cardiovascular medicine, and neurodegeneration. As targeted therapies multiply, assay menus will expand and testing will move earlier in the patient journey. Decentralized and point-of-care molecular platforms will improve access in emerging markets. Diagnostics companies with integrated sequencing, software, and evidence-generation capabilities will gain market power. Reimbursement will increasingly depend on demonstrated improvements in survival, quality of life, or reduction in ineffective treatment. By 2035, biomarker-guided prescribing is expected to be a routine component of specialty care.

Conclusion
Companion diagnostics are converting precision medicine from a concept into routine clinical practice. By linking diagnostic results directly to therapeutic decisions, they improve patient outcomes and create a more efficient drug development ecosystem. The strongest market participants will be those able to combine assay accuracy, regulatory expertise, data analytics, and payer evidence.

FAQ
Q1: What is a companion diagnostic?
A: A companion diagnostic is a test used to determine whether a patient is likely to benefit from a specific therapy. It helps clinicians select the right treatment for the right patient. These tests are commonly used in oncology for targeted therapies and immunotherapies. They reduce trial-and-error prescribing. They also improve safety and treatment efficiency.

Q2: Why are pharmaceutical companies investing in companion diagnostics?
A: Biomarker-based patient selection improves clinical trial success rates and can reduce cohort sizes. It also helps demonstrate therapeutic benefit to regulators and payers. Companion diagnostics support targeted drug commercialization after approval. Partnerships with diagnostic firms create a reliable testing pathway at launch. This makes precision therapies more accessible and commercially sustainable.

#Biomarkers #CompanionDiagnostics #TargetedTherapy #PrecisionOncology